Marimastat produces comparable survival rates to chemotherapy in some advanced pancreatic cancer patients

Marimastat, a matrix metalloproteinase inhibitor, offers a similar survival benefit to chemotherapy in patients with non-metastatic pancreatic cancer, but with fewer side effects, reports an international team of researchers from the United States and Britain.

The randomized clinical trial compared the effects of three different doses of marimastat with the chemotherapy drug gemcitabine in 414 patients with advanced pancreatic cancer. During this clinical trial, gemcitabine was approved for use in pancreatic cancer, and is now considered the standard of care.

According to the study, the one-year survival rate for patients with localized cancer was 20 percent for patients given the highest dose of marimastat and 19 percent for patients treated with gemcitabine. Although patients taking gemcitabine reported greater improvements in pain and mood, fewer toxic side effects (e.g., pulmonary complications and nausea) were reported in patients taking marimastat versus gemcitabine (12 percent versus 22 percent, respectively).

Marimastat did not show benefit in lower doses or in patients with metastatic pancreatic cancer. The one-year survival rate for patients taking lower doses of marimastat was 14 percent.

Researchers say marimastat appears to benefit some non-metastatic patients and suggest the agent be tested in those patients in combination with gemcitabine. "Five years ago, patients with advanced pancreatic cancer did not have any good treatment options, but gemcitabine and newly engineered drugs like marimastat are giving us hope," says the study leader Simon Bramhall, from the Queen Elizabeth Hospital, Birmingham, England. "These clinical trial results are encouraging and suggest that targeted molecular therapy may benefit some patients."

Matrix metalloproteinase inhibitors restrict the growth and spread of solid tumors by blocking blood vessel growth to the site of tumors. Marimastat is also being tested in ovarian a

Contact: Carrie Bittman
American Society of Clinical Oncology

Page: 1 2

Related biology news :

1. Genetic modification of linseed produces healthier omega 3 and 6 fatty acids
2. Spontaneous mutation produces new MAO A/B knockout mouse
3. Synthetic hormone used in contraceptives and HRT produces negative effects in monkey studies
4. Tigecycline - Candidate antibiotic produces 74 percent cure rate in cSSSI patients
5. First genetic comparison of purebred domestic dogs produces surprises
6. Biological computer diagnoses cancer and produces drug in a test tube
7. High-fat fast-food breakfast produces rush of inflammatory factors into blood stream, UB study finds
8. Oil exploitation in Ecuadors Amazon basin produces a public health emergency
9. Method produces uniform, self-assembled nanocells
10. Scientists develop plant that produces potential anti-carcinogen
11. Brains master molecule produces same behavior in mice from three different psychostimulant drugs

Post Your Comments:

(Date:9/30/2015)... Fla. , Sept. 30, 2015  The U.S. ... month issued another key ruling in favor of ... that Korean fingerprint scanner company Suprema and its U.S. ... of 1930, a trade provision that declares it unlawful ... trade, by infringing two of Crossmatch,s patents, the 5,900,993 ...
(Date:9/28/2015)...  The monitoring of vital signs, such as ... an essential component of patient assessment. Changes in ... a patient,s condition. However, in general care areas ... during routine observation rounds only once every four ... these observation rounds, the warning signs can go ...
(Date:9/24/2015)... NEW YORK , Sept. 24, 2015  EyeLock ... will be showcasing its award winning and latest technology ... Anaheim, California . EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA.   EyeLock,s platform uses video technology to deliver a ...
Breaking Biology News(10 mins):
(Date:10/13/2015)... ... October 13, 2015 , ... SonaCare ... announced today that it received de novo clearance from the U.S. Food and ... the ablation of prostate tissue. Sonablate® is the first High Intensity Therapeutic Ultrasound ...
(Date:10/12/2015)... Calif. and BRUSSELS , Oct. ... (Euronext Brussels: UCB) today presented additional findings from an exploratory ... The findings were presented today in an oral plenary ... (ASBMR) 2015 Annual Meeting in Seattle . ... --> The small exploratory sub-study data showed ...
(Date:10/12/2015)... 12, 2015  Rebiotix Inc. today announced that ... its lead Microbiota Restoration Therapy (MRT) RBX2660 as ... Clostridium difficile (C diff) infection, a ... 29,000 deaths in the U.S. annually. 1 ... was founded to revolutionize the treatment of debilitating ...
(Date:10/12/2015)... SAN DIEGO , Oct. 12, 2015 /PRNewswire/ ... for debilitating allergic and inflammatory diseases and conditions, ... Series A preferred stock financing. Concurrent with the ... also entered into a Loan and Security Agreement ... borrow up to $7 million. Patara will use ...
Breaking Biology Technology:
Cached News: